Allovir, Inc. is a clinical-stage cell therapy company focused on developing allogenic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Their lead product, posoleucel, is an allogenic, off-the-shelf VST therapy designed to treat various viruses. Allovir, Inc. has several other preclinical and clinical development product candidates in their pipeline, including treatments for COVID-19, hepatitis B, and other viral diseases.